// App-Quantinova.ai

9014 : Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

Researchers

Presenter

  • Tara C. Gangadhar

Principal Investigators

  • Bryan J. Schneider

  • Todd Michael Bauer

  • Jeffrey S. Wasser

  • Alexander I. Spira

  • Sandip P. Patel

  • Ani Sarkis Balmanoukian

  • Joshua Bauml

  • Emmett V. Schmidt

  • Yufan Zhao

  • Mark M. Jones

  • Ahmad A. Tarhini

Medical Centers

  • Abramson Cancer Center, Philadelphia, PA

  • University of Michigan, Ann Arbor, MI

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • University of Connecticut Health Center, Farmington, CT

  • Virginia Cancer Specialists Research Institute, Fairfax, VA

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Merck & Co., Inc., Kenilworth, NJ

  • Incyte Corporation, Wilmington, DE

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

Locations

  • United States

Companies

  • Merck & Co., Inc.

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • epacadostat

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • NCT02178722

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved